142 related articles for article (PubMed ID: 23011220)
1. Prediction of amyloid-β pathology in amnestic mild cognitive impairment with neuropsychological tests.
Bahar-Fuchs A; Villemagne V; Ong K; Chetélat G; Lamb F; Reininger CB; Woodward M; Rowe CC
J Alzheimers Dis; 2013; 33(2):451-62. PubMed ID: 23011220
[TBL] [Abstract][Full Text] [Related]
2. Elucidating the Risk Factors for Progression from Amyloid-Negative Amnestic Mild Cognitive Impairment to Dementia.
Kim HJ; Lee JH; Cheong EN; Chung SE; Jo S; Shim WH; Hong YJ
Curr Alzheimer Res; 2020; 17(10):893-903. PubMed ID: 33256581
[TBL] [Abstract][Full Text] [Related]
3. Dual Time-Point [18F]Florbetaben PET Delivers Dual Biomarker Information in Mild Cognitive Impairment and Alzheimer's Disease.
Florek L; Tiepolt S; Schroeter ML; Berrouschot J; Saur D; Hesse S; Jochimsen T; Luthardt J; Sattler B; Patt M; Hoffmann KT; Villringer A; Classen J; Gertz HJ; Sabri O; Barthel H
J Alzheimers Dis; 2018; 66(3):1105-1116. PubMed ID: 30400095
[TBL] [Abstract][Full Text] [Related]
4. Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study.
Ong KT; Villemagne VL; Bahar-Fuchs A; Lamb F; Langdon N; Catafau AM; Stephens AW; Seibyl J; Dinkelborg LM; Reininger CB; Putz B; Rohde B; Masters CL; Rowe CC
J Neurol Neurosurg Psychiatry; 2015 Apr; 86(4):431-6. PubMed ID: 24970906
[TBL] [Abstract][Full Text] [Related]
5. The Role of Free and Cued Selective Reminding Test in Predicting [18F]Florbetaben PET Results in Mild Cognitive Impairment and Mild Dementia.
Spallazzi M; Michelini G; Barocco F; Dieci F; Copelli S; Messa G; Scarlattei M; Pavesi G; Ruffini L; Caffarra P
J Alzheimers Dis; 2020; 73(4):1647-1659. PubMed ID: 31958094
[TBL] [Abstract][Full Text] [Related]
6. Neuropsychological Testing Predicts Cerebrospinal Fluid Amyloid-β in Mild Cognitive Impairment.
Kandel BM; Avants BB; Gee JC; Arnold SE; Wolk DA;
J Alzheimers Dis; 2015; 46(4):901-12. PubMed ID: 25881908
[TBL] [Abstract][Full Text] [Related]
7. Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnestic Mild Cognitive Impairment-Storage Subtype.
Espinosa A; Alegret M; Pesini P; Valero S; Lafuente A; Buendía M; San José I; Ibarria M; Tejero MA; Giménez J; Ruiz S; Hernández I; Pujadas F; Martínez-Lage P; Munuera J; Arbizu J; Tárraga L; Hendrix SB; Ruiz A; Becker JT; Landau SM; Sotolongo-Grau O; Sarasa M; Boada M; ;
J Alzheimers Dis; 2017; 57(2):447-459. PubMed ID: 28269787
[TBL] [Abstract][Full Text] [Related]
8. Brain structural, functional, and cognitive correlates of recent versus remote autobiographical memories in amnestic Mild Cognitive Impairment.
Tomadesso C; Perrotin A; Mutlu J; Mézenge F; Landeau B; Egret S; de la Sayette V; Jonin PY; Eustache F; Desgranges B; Chételat G
Neuroimage Clin; 2015; 8():473-82. PubMed ID: 26106572
[TBL] [Abstract][Full Text] [Related]
9. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
10. Feasibility and acceptance of simultaneous amyloid PET/MRI.
Schütz L; Lobsien D; Fritzsch D; Tiepolt S; Werner P; Schroeter ML; Berrouschot J; Saur D; Hesse S; Jochimsen T; Rullmann M; Sattler B; Patt M; Gertz HJ; Villringer A; Claßen J; Hoffmann KT; Sabri O; Barthel H
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2236-2243. PubMed ID: 27435367
[TBL] [Abstract][Full Text] [Related]
11. The Incremental Diagnostic Value of [18F]Florbetaben PET and the Pivotal Role of the Neuropsychological Assessment in Clinical Practice.
Spallazzi M; Barocco F; Michelini G; Morelli N; Scarlattei M; Baldari G; Ruffini L; Caffarra P
J Alzheimers Dis; 2019; 67(4):1235-1244. PubMed ID: 30689568
[TBL] [Abstract][Full Text] [Related]
12. Differential patterns of regional cerebral hypometabolism according to the level of cerebral amyloid deposition in patients with amnestic mild cognitive impairment.
Jeon SY; Yi D; Byun MS; Choi HJ; Kim HJ; Lee JH; Baek H; Choe YM; Lee Y; Woo JI; Lee DY
Neurosci Lett; 2016 Oct; 632():104-8. PubMed ID: 27574728
[TBL] [Abstract][Full Text] [Related]
13. Cognitive decline in adults with amnestic mild cognitive impairment and high amyloid-β: prodromal Alzheimer's disease?
Lim YY; Ellis KA; Harrington K; Pietrzak RH; Gale J; Ames D; Bush AI; Darby D; Martins RN; Masters CL; Rowe CC; Savage G; Szoeke C; Villemagne VL; Maruff P
J Alzheimers Dis; 2013; 33(4):1167-76. PubMed ID: 23160011
[TBL] [Abstract][Full Text] [Related]
14. Brain metabolism and cerebrospinal fluid biomarkers profile of non-amnestic mild cognitive impairment in comparison to amnestic mild cognitive impairment and normal older subjects.
Coutinho AM; Porto FH; Duran FL; Prando S; Ono CR; Feitosa EA; Spíndola L; de Oliveira MO; do Vale PH; Gomes HR; Nitrini R; Brucki SM; Buchpiguel CA
Alzheimers Res Ther; 2015 Sep; 7(1):58. PubMed ID: 26373380
[TBL] [Abstract][Full Text] [Related]
15. Can we predict amyloid deposition by objective cognition and regional cerebral blood flow in patients with subjective cognitive decline?
Funaki K; Nakajima S; Noda Y; Wake T; Ito D; Yamagata B; Yoshizaki T; Kameyama M; Nakahara T; Murakami K; Jinzaki M; Mimura M; Tabuchi H
Psychogeriatrics; 2019 Jul; 19(4):325-332. PubMed ID: 30688000
[TBL] [Abstract][Full Text] [Related]
16. The relative importance of imaging markers for the prediction of Alzheimer's disease dementia in mild cognitive impairment - Beyond classical regression.
Teipel SJ; Kurth J; Krause B; Grothe MJ;
Neuroimage Clin; 2015; 8():583-93. PubMed ID: 26199870
[TBL] [Abstract][Full Text] [Related]
17. Proper names from story recall are associated with beta-amyloid in cognitively unimpaired adults at risk for Alzheimer's disease.
Mueller KD; Koscik RL; Du L; Bruno D; Jonaitis EM; Koscik AZ; Christian BT; Betthauser TJ; Chin NA; Hermann BP; Johnson SC
Cortex; 2020 Oct; 131():137-150. PubMed ID: 32861209
[TBL] [Abstract][Full Text] [Related]
18. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
19. Prediction of Alzheimer's Dementia in Patients with Amnestic Mild Cognitive Impairment in Clinical Routine: Incremental Value of Biomarkers of Neurodegeneration and Brain Amyloidosis Added Stepwise to Cognitive Status.
Lange C; Suppa P; Pietrzyk U; Makowski MR; Spies L; Peters O; Buchert R;
J Alzheimers Dis; 2018; 61(1):373-388. PubMed ID: 29154285
[TBL] [Abstract][Full Text] [Related]
20. Episodic Memory, Hippocampal Volume, and Function for Classification of Mild Cognitive Impairment Patients Regarding Amyloid Pathology.
Miotto EC; Brucki SMD; Cerqueira CT; Bazán PR; Silva GAA; Martin MDGM; da Silveira PS; Faria DP; Coutinho AM; Buchpiguel CA; Busatto Filho G; Nitrini R
J Alzheimers Dis; 2022; 89(1):181-192. PubMed ID: 35871330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
